Submitted by kBLASTER Team on
by PRNewswire
Reinforcing its commitment to enabling confident diagnosis through innovation, Royal Philips (NYSE: PHG) today announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its IQon Spectral CT, presenting an entirely new approach to spectral imaging. This first-of-its kind technology adds a new dimension to Computed Tomography (CT) imaging, delivering anatomical information and offering the ability to characterize structures based on their material content within a single scan. The enhanced image quality may help improve confidence in diagnoses and deliver operational efficiency.
Search kBLASTER for FDA 510(k) predicates with effective result management to build your successful 510(k) clearance strategy.